SonoThera to Present at ASN Kidney Week 2024 Demonstrating the Potential of Novel Nonviral Ultrasound-Mediated Gene Therapy ...

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

Rossetti S, Consugar MB, Chapman AB, et al.: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 2143–60 CrossRef CrossRef e3. Hateboer N, v ...

APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Detailed price information for Xortx Therapeutics Inc (XRTX-X) from The Globe and Mail including charting and trades.

Regulus (RGLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and ...

The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD ...

This research used cell-based signaling assay and Gaussian-accelerated molecular dynamics (GaMD) to study peptide-mediated signaling activation of Polycystin-1 (PC1), which is responsible for the ...

New Delhi: Vitus Care has expressed concern over the fact that in India, the incidence of end-stage renal disease (ESRD) is rising at an alarming rate, particularly among adults aged 25-55.